Mazdutide by Dragon Pharma
What Is Mazdutide?
Mazdutide is a synthetic dual receptor agonist that targets both the glucagon (GCG) receptor and the GLP-1 receptor. The GLP-1 component suppresses appetite and stabilizes glucose, while the glucagon component raises energy expenditure, which is why the combination is studied for weight management and type 2 diabetes.
Dragon Pharma supplies Mazdutide as a lyophilized research peptide for reconstitution with bacteriostatic water. In clinical programs Mazdutide is given once weekly by subcutaneous injection, and phase 3 results in adults with obesity have shown substantial body weight reduction. In bodybuilding and lifestyle research it is used as a metabolic tool for fat-loss phases where appetite control is the main obstacle.
Each vial holds 10 mg of Mazdutide by Dragon Pharma for a 10 mg per ml concentration after standard reconstitution. Mazdutide is a research peptide, not an approved medicine in most countries, and is intended for laboratory research only.
Mazdutide Research Use
Mazdutide is a once-weekly peptide in clinical research. Published clinical data describe doses of 4-6 mg injected subcutaneously each week, with the protocol starting lower and titrating up to reduce gastrointestinal side effects.
| Reference | Detail |
|---|---|
| Reconstitution | 1 ml bacteriostatic water = 10 mg per ml |
| Starting reference | 2.5-3 mg once weekly, subcutaneous |
| Clinical reference | 4-6 mg once weekly after titration |
| Schedule | Weekly injection, same day each week |
- Use only sterile bacteriostatic water for reconstitution
- Rotate injection sites and refrigerate after mixing
- Monitor appetite, glucose and gastrointestinal tolerance closely
Practical Notes
Mazdutide is a potent metabolic peptide. All doses above are research and clinical references, not instructions, and must be validated by the researcher.
Mazdutide Stacks
Mazdutide is used in structured fat-loss phases, so it is paired with compounds that support muscle retention, conditioning and metabolic efficiency. All rows below link to same-brand Dragon Pharma products.
| Combination | Why it is combined |
|---|---|
| Tirze-Pep 10mg | Alternative incretin-based reference for extended metabolic protocols |
| Anavar 10 | Appetite-controlled cutting with strength and muscle retention |
| AOD 9604 5 mg | Adds a lipolysis-focused fragment analog to the fat-loss protocol |
| L-Carnitine 500 | Metabolic efficiency and conditioning support during the deficit |
Mazdutide Side Effects
As with other GLP-1 class peptides, gastrointestinal effects dominate the side effect profile of Mazdutide, especially during dose titration. Nausea is the most common complaint and usually fades as the dose stabilizes.
- Nausea, vomiting, diarrhea or constipation
- Suppressed appetite beyond the intended level
- Injection site redness or discomfort
- Hypoglycemia risk when combined with insulin or sulfonylureas
- Possible gallbladder-related events reported in long-term GLP-1 use
Mazdutide is a research peptide. It is not approved for human or veterinary use in most regions. Reconstitute only with sterile bacteriostatic water and store the vial out of reach of children.
For research use only. Nothing on this page is medical advice; metabolic peptide protocols belong in a qualified laboratory setting.
What is Mazdutide?
Mazdutide is a synthetic peptide that activates both the GLP-1 receptor and the glucagon receptor. This dual mechanism suppresses appetite while increasing energy expenditure, which makes it a focus of obesity and diabetes research.
What does the glucagon component add to a GLP-1 peptide?
GLP-1 alone reduces appetite and slows gastric emptying, while glucagon receptor activation increases energy expenditure and fat oxidation. The dual action is designed to improve weight loss beyond single GLP-1 agonists.
How is Mazdutide different from semaglutide and tirzepatide?
Semaglutide targets only the GLP-1 receptor, and tirzepatide targets GLP-1 plus GIP. Mazdutide combines GLP-1 with glucagon agonism, which is a different second mechanism aimed at calorie burn as well as appetite.
How is Mazdutide dosed in research?
Clinical programs use once-weekly subcutaneous dosing, starting low and titrating up, with phase 3 protocols reaching 4-6 mg weekly. Reconstitution follows standard peptide practice with bacteriostatic water.
How much weight loss can Mazdutide produce?
Phase 3 data in adults with obesity showed clinically meaningful weight reduction, and a 9 mg weekly dose achieved over 20% mean weight loss after one year in a trial without diabetes. Results vary individually.
Does Mazdutide cause nausea?
Nausea and other gastrointestinal effects are the most common side effects, especially during the first weeks and as the dose rises. A slow titration schedule is the standard way to reduce them.
Is Mazdutide approved anywhere?
Mazdutide has been approved in China as the first GCG/GLP-1 dual receptor agonist for type 2 diabetes and weight management, and it remains in clinical development in other regions. Dragon Pharma sells it as a research peptide.
Can Mazdutide be combined with other peptides?
Researchers sometimes compare or combine it with other incretin-based peptides such as Tirze-Pep, or pair it with muscle-retention compounds during a deficit. Any combination needs careful glucose and side effect monitoring.
Who should avoid Mazdutide in research?
Researchers should avoid Mazdutide where there is a history of medullary thyroid tumors, pancreatitis or severe gastrointestinal disease. Combining it with insulin or sulfonylureas carries a real hypoglycemia risk.
Is Mazdutide safe for long-term use?
Long-term safety continues to be studied in phase 3 programs, with gastrointestinal and gallbladder events among the tracked concerns. Because it is a research peptide, no long-term human safety data exist for this specific product.
Related Products
